410 related articles for article (PubMed ID: 35384056)
61. Virtual screening of anti-HIV1 compounds against SARS-CoV-2: machine learning modeling, chemoinformatics and molecular dynamics simulation based analysis.
Nand M; Maiti P; Joshi T; Chandra S; Pande V; Kuniyal JC; Ramakrishnan MA
Sci Rep; 2020 Nov; 10(1):20397. PubMed ID: 33230180
[TBL] [Abstract][Full Text] [Related]
62. Plant-Derived Antiviral Compounds as Potential Entry Inhibitors against Spike Protein of SARS-CoV-2 Wild-Type and Delta Variant: An Integrative in SilicoApproach.
Ambrose JM; Kullappan M; Patil S; Alzahrani KJ; Banjer HJ; Qashqari FSI; Raj AT; Bhandi S; Veeraraghavan VP; Jayaraman S; Sekar D; Agarwal A; Swapnavahini K; Krishna Mohan S
Molecules; 2022 Mar; 27(6):. PubMed ID: 35335139
[TBL] [Abstract][Full Text] [Related]
63. Attention Mechanism-Based Graph Neural Network Model for Effective Activity Prediction of SARS-CoV-2 Main Protease Inhibitors: Application to Drug Repurposing as Potential COVID-19 Therapy.
Wu Y; Li K; Li M; Pu X; Guo Y
J Chem Inf Model; 2023 Nov; 63(22):7011-7031. PubMed ID: 37960886
[TBL] [Abstract][Full Text] [Related]
64. In-silico evaluation of natural alkaloids against the main protease and spike glycoprotein as potential therapeutic agents for SARS-CoV-2.
Shah M; Yamin R; Ahmad I; Wu G; Jahangir Z; Shamim A; Nawaz H; Nishan U; Ullah R; Ali EA; Sheheryar ; Chen K
PLoS One; 2024; 19(1):e0294769. PubMed ID: 38175855
[TBL] [Abstract][Full Text] [Related]
65. Determination of potential inhibitors based on isatin derivatives against SARS-CoV-2 main protease (m
Badavath VN; Kumar A; Samanta PK; Maji S; Das A; Blum G; Jha A; Sen A
J Biomol Struct Dyn; 2022 Apr; 40(7):3110-3128. PubMed ID: 33200681
[TBL] [Abstract][Full Text] [Related]
66. Molecular Docking and Virtual Screening Based Prediction of Drugs for COVID-19.
Talluri S
Comb Chem High Throughput Screen; 2021; 24(5):716-728. PubMed ID: 32798373
[TBL] [Abstract][Full Text] [Related]
67. SARS-CoV-2 M
Bharadwaj S; Azhar EI; Kamal MA; Bajrai LH; Dubey A; Jha K; Yadava U; Kang SG; Dwivedi VD
J Biomol Struct Dyn; 2022 Apr; 40(6):2769-2784. PubMed ID: 33150855
[TBL] [Abstract][Full Text] [Related]
68. Elucidating biophysical basis of binding of inhibitors to SARS-CoV-2 main protease by using molecular dynamics simulations and free energy calculations.
Sk MF; Roy R; Jonniya NA; Poddar S; Kar P
J Biomol Struct Dyn; 2021 Jul; 39(10):3649-3661. PubMed ID: 32396767
[TBL] [Abstract][Full Text] [Related]
69. Pea eggplant (
Govender N; Zulkifli NS; Badrul Hisham NF; Ab Ghani NS; Mohamed-Hussein ZA
PeerJ; 2022; 10():e14168. PubMed ID: 36518265
[TBL] [Abstract][Full Text] [Related]
70. Molecular modeling of some commercially available antiviral drugs and their derivatives against SARS-CoV-2 infection.
Arman M; Alam S; Maruf RA; Shams Z; Islam MN
Narra J; 2024 Apr; 4(1):e319. PubMed ID: 38798846
[TBL] [Abstract][Full Text] [Related]
71. Targeting the 3CLpro and RdRp of SARS-CoV-2 with phytochemicals from medicinal plants of the Andean Region: molecular docking and molecular dynamics simulations.
Mosquera-Yuqui F; Lopez-Guerra N; Moncayo-Palacio EA
J Biomol Struct Dyn; 2022 Mar; 40(5):2010-2023. PubMed ID: 33084512
[TBL] [Abstract][Full Text] [Related]
72. Plant-derived chemicals as potential inhibitors of SARS-CoV-2 main protease (6LU7), a virtual screening study.
Sisakht M; Mahmoodzadeh A; Darabian M
Phytother Res; 2021 Jun; 35(6):3262-3274. PubMed ID: 33759279
[TBL] [Abstract][Full Text] [Related]
73. Phytoconstituents of Artemisia Annua as potential inhibitors of SARS CoV2 main protease: an in silico study.
Irfan E; Dilshad E; Ahmad F; Almajhdi FN; Hussain T; Abdi G; Waheed Y
BMC Infect Dis; 2024 May; 24(1):495. PubMed ID: 38750422
[TBL] [Abstract][Full Text] [Related]
74. Computational studies indicated the effectiveness of human metabolites against SARS-Cov-2 main protease.
Roy R; Sk MF; Tanwar O; Kar P
Mol Divers; 2023 Aug; 27(4):1587-1602. PubMed ID: 35978064
[TBL] [Abstract][Full Text] [Related]
75. Antiviral peptides inhibiting the main protease of SARS-CoV-2 investigated by computational screening and in vitro protease assay.
Stewart J; Shawon J; Ali MA; Williams B; Shahinuzzaman ADA; Rupa SA; Al-Adhami T; Jia R; Bourque C; Faddis R; Stone K; Sufian MA; Islam R; McShan AC; Rahman KM; Halim MA
J Pept Sci; 2024 Apr; 30(4):e3553. PubMed ID: 38031661
[TBL] [Abstract][Full Text] [Related]
76. In-silico screening for identification of potential inhibitors against SARS-CoV-2 transmembrane serine protease 2 (TMPRSS2).
Barge S; Jade D; Gosavi G; Talukdar NC; Borah J
Eur J Pharm Sci; 2021 Jul; 162():105820. PubMed ID: 33775827
[TBL] [Abstract][Full Text] [Related]
77. In silico prediction of SARS-CoV-2 main protease and polymerase inhibitors: 3D-Pharmacophore modelling.
Mosayebnia M; Hajiagha Bozorgi A; Rezaeianpour M; Kobarfard F
J Biomol Struct Dyn; 2022 Sep; 40(14):6569-6586. PubMed ID: 33599180
[TBL] [Abstract][Full Text] [Related]
78. Machine learning combines atomistic simulations to predict SARS-CoV-2 Mpro inhibitors from natural compounds.
Nguyen TH; Thai QM; Pham MQ; Minh PTH; Phung HTT
Mol Divers; 2024 Apr; 28(2):553-561. PubMed ID: 36823394
[TBL] [Abstract][Full Text] [Related]
79. Molecular screening of antimalarial, antiviral, anti-inflammatory and HIV protease inhibitors against spike glycoprotein of coronavirus.
Prashantha CN; Gouthami K; Lavanya L; Bhavanam S; Jakhar A; Shakthiraju RG; Suraj V; Sahana KV; Sujana HS; Guruprasad NM; Ramachandra R
J Mol Graph Model; 2021 Jan; 102():107769. PubMed ID: 33152616
[TBL] [Abstract][Full Text] [Related]
80. Exploration of natural compounds with anti-SARS-CoV-2 activity via inhibition of SARS-CoV-2 Mpro.
Bharadwaj S; Dubey A; Yadava U; Mishra SK; Kang SG; Dwivedi VD
Brief Bioinform; 2021 Mar; 22(2):1361-1377. PubMed ID: 33406222
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
